Pancreatic Cancer Research

ResearcherSalk Institute for Biological StudiesActive in the last 2 years

Dannielle D. Engle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1876-7675; OpenAlex author ID A5070163624; NIH RePORTER profile ID 8470670. Sources: funder_awards.

Their work

Papers
25 (first author 1, last author 4)
Trials
0
Grants
4
Labs led
1
Collaborators
115
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 1 paper, 1 grant · 2018: 3 papers · 2019: 3 papers, 1 grant · 2020: none · 2021: 1 paper, 1 grant · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers, 1 grant

Papers 25

  1. Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy. First author DOI 10.1158/0008-5472.can-25-5676↗
  2. CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation Last author DOI 10.64898/2026.04.08.717301↗
  3. Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment Co-author DOI 10.64898/2026.04.14.718544↗
  4. CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.05.22.727290↗
  5. Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer Co-author DOI 10.1101/2025.05.29.656904↗
  6. The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids. Last author DOI 10.1172/jci.insight.172419↗
  7. A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer. Co-author DOI 10.1038/s41467-023-40798-6↗
  8. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
  9. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-1313↗
  10. Altered glycosylation in pancreatic cancer and beyond. Last author DOI 10.1084/jem.20211505↗
  11. The autophagy initiating kinase ULK1 is required for pancreatic cancer cell growth and survival Co-author DOI 10.1101/2021.05.15.444304↗
  12. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Co-author DOI 10.1126/science.aaw3145↗
  13. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1398↗
  14. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-19-0094↗
  15. Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3876↗
  16. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  17. Dynamic changes during the treatment of pancreatic cancer. Co-author DOI 10.18632/oncotarget.24483↗
  18. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. Co-author DOI 10.1084/jem.20162024↗
  19. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Co-author DOI 10.1038/ncb3340↗
  20. Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Co-author DOI 10.1038/ncb3377↗
  21. Model organoids provide new research opportunities for ductal pancreatic cancer. Co-author DOI 10.1080/23723556.2015.1014757↗
  22. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Co-author DOI 10.1158/0008-5472.can-16-1201↗
  23. Organoid models of human and mouse ductal pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.12.021↗
  24. Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling. Co-author DOI 10.1158/0008-5472.can-14-2645↗
  25. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗

Grants 4

  1. Core 3: Mouse Models Core (MM Core) P01CA265762↗
  2. Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer R00CA204725↗
  3. CA 19-9 Promotes Pancreatitis and Pancreatic Cancer AWARD pancan:2019-dannielle-engle-phd-ca-19-9-promotes-pancreatitis-and-pancre
  4. Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer K99CA204725↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hervé Tiriac · 16 shared papers, 2014–2026 · strength 2.52
  2. Ronald M. Evans · 6 shared papers, 1 shared grant, 2014–2026 · strength 1.53
  3. Andrew M. Lowy · 7 shared papers, 2023–2026 · strength 1.33
  4. Tony R. Hunter · 3 shared papers, 1 shared grant, 2014–2026 · strength 1.07
  5. Reuben Shaw · 2 shared papers, 1 shared grant, 2021–2026 · strength 1.01
  6. Jan C. Lumibao · 5 shared papers, 2021–2026 · strength 0.86
  7. Satoshi Ogawa · 4 shared papers, 2023–2026 · strength 0.84
  8. Geoffrey Myles Wahl · 1 shared paper, 1 shared grant, 2014–2026 · strength 0.74
  9. Herve Tiriac · 1 shared grant, 2026 · strength 0.71
  10. Casie S. Kubota · 3 shared papers, 2026 · strength 0.68
  11. David Arthur Tuveson · 12 shared papers, 2014–2019 · strength 0.66
  12. Jasper Hsu · 3 shared papers, 2022–2026 · strength 0.65
  13. Christian M. Metallo · 2 shared papers, 2025–2026 · strength 0.43
  14. Hyemin Song · 2 shared papers, 2026 · strength 0.42
  15. Jonathan Weitz · 2 shared papers, 2023–2026 · strength 0.41
  16. Sonja N. Brun · 2 shared papers, 2021–2025 · strength 0.29
  17. Nicholas D. P. Cosford · 2 shared papers, 2021–2025 · strength 0.29
  18. Youngkyu Park · 5 shared papers, 2015–2019 · strength 0.29
  19. Anna Trimble · 1 shared paper, 2026 · strength 0.26
  20. Corina E. Antal · 2 shared papers, 2023 · strength 0.25
  21. Haiyong Han · 2 shared papers, 2023 · strength 0.25
  22. Daniel D. Von Hoff · 2 shared papers, 2023 · strength 0.25
  23. Kenneth H. Yu · 4 shared papers, 2015–2019 · strength 0.24
  24. Lindsey A. Baker · 4 shared papers, 2015–2019 · strength 0.22
  25. Chang‐Il Hwang · 4 shared papers, 2015–2019 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.